Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19 CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...

PAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update Conference call to be held today at 4:30 p.m. Eastern time NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated,...

Biofrontera provides clinical development updates Leverkusen, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an...

Biofrontera Reports Positive Phase III Results with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical...